Rituxan rituximab regulatory update

Genentech said FDA approved an sBLA for Rituxan rituximab as a 90-minute infusion for previously untreated follicular non-Hodgkin's lymphoma (NHL) and diffuse large B cell lymphoma (DLBCL) patients who tolerated a standard 3 to 4 hour infusion in the first cycle. The chimeric mAb against CD20 antigen is approved in the U.S. to treat NHL, chronic lymphocytic leukemia (CLL) and rheumatoid arthritis (RA), Wegener's granulomatosis and microscopic polyangiitis. ...